Tekla Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Tekla Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-56,900	Closed	-$2.55M	–	168
2017 Q3	$2.55M	Hold	56,900	–	–	0.09%	109
2017 Q2	$1.7M	Hold	56,900	–	–	0.06%	116
2017 Q1	$1.26M	Hold	56,900	–	–	0.05%	124
2016 Q4	$1.07M	Sell	56,900 -125,100	-69%	-$3.06M	0.05%	128
2016 Q3	$5.46M	Hold	182,000	–	–	0.21%	83
2016 Q2	$7M	Hold	182,000	–	–	0.29%	75
2016 Q1	$6.93M	Hold	182,000	–	–	0.29%	70
2015 Q4	$8M	Hold	182,000	–	–	0.29%	71
2015 Q3	$7.41M	Buy	+182,000	New	+$7.98M	0.27%	83

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Tekla Capital Management's JUNO Position: Q4 2017 in Review

Tekla Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 56,900 shares — an estimated $2.55M sold.

Tekla Capital Management first reported a position in JUNO in Q3 2015 and held it in 9 quarters. The position peaked at $8M in Q4 2015. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

Tekla Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Tekla Capital Management sold 56,900 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $2.55M.
Tekla Capital Management first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 9 quarters.
Tekla Capital Management's Juno Therapeutics, Inc. position peaked at $8M in Q4 2015.
237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.